"Risky business" ten years is not a lifetime

Circulation

Volumn 119, Issue 3, 2009, Pages 362-364

  Nambi, Vijay ^a   Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Coronary disease; Editorials; Prevention; Risk factors

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 9P; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; EDITORIAL; GENOTYPE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; PRIMARY PREVENTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CORONARY ARTERY DISEASE; LIFE EXPECTANCY; METABOLISM; MORTALITY; NOTE; RISK FACTOR;

BIOLOGICAL MARKERS; CORONARY DISEASE; HUMANS; LIFE EXPECTANCY; RISK FACTORS;

EID: 60549098958     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.830281     Document Type: Editorial

References (9)

1. Hemann BA, Bimson WF, Taylor AJ. The Framingham Risk Score: an appraisal of its benefits and limitations. Am Heart Hosp J. 2007;5:91-96.
2. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-619.
3. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwanz RS, Riley WA, Mendes RA, Douglas P, Shah PK. From vulnerable plaque to vulnerable patient, part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98:2H-15H.
4. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
5. Berry JD, Liu K, Folsom AR, Lewis CE, Carr JJ, Polak JF, Shea S, Sidney S, O'Leary DH, Chan C, Lloyd-Jones DM. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the Coronary Artery Risk Development in Young Adults Study and Multi-Ethnic Study of Atherosclerosis. Circulation. 2009;119:382-389.
6. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
7. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
8. Nambi V, Chambless L, Folsom AR, Hu Y, Mosley T, Volcik K, Boerwinkle E, Ballantyne CM. Are all patients considered "low risk" for coronary heart disease really low risk? An analysis from the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2008;118(suppl 2):S1125. Abstract.
9. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798.